US3944660A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition
Assignee: Biorex Laboratories Ltd
•
Filing: 1973-11-28
•
Granted: 1976-03-16
•
Expires: 1993-11-28
Abstract
Abstract There is provided a pharmaceutical composition in dosage unit form comprising (a) 1 - 100 mg. of glycyrrhetinic acid and/or of at least one anti-inflammatory active derivative thereof, in admixture with (b) 1 - 50% by weight of alginic acid and/or at least one non-toxic salt thereof and/or of at least one carboxyalkyl-cellulose and/or of at least one non-toxic salt thereof, (c) 1 - 30% by weight of at least one non-toxic carbonate and/or bicarbonate and (d) 0 - 30% by weight of at least one antacid compound.
Inventors
- 👤 Siegfried Gottfried
- 👤 Lily Baxendale
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065; A61K33/00; A61K33/06; A61K33/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
198 words
A pharmaceutical composition in uncoated tablet dosage unit form useful for treating oesophagitis comprising (a) 1-100 mg. of at least one member selected from the group consisting of glycyrrhetinic acid, the hemiesters thereof, and the salts of the hemiesters, in admixture with (b) 1-50% by weight of at least one member selected from the group consisting of alginic acid, the non-toxic salts of alginic acid, the carboxyalkyl-cellulose and the non-toxic salts of the carboxyalkyl-celluloses, (c) 1-30% by weight of at least one member selected from the group consisting of the non-toxic carbonates and bicarbonates and (d) 0-30% by weight of at least one antacid compound selected from the group consisting of aluminum hydroxide, aluminum phosphate, dihydroxyaluminum aminoacetate, magnesium hydroxide, and magnesium trisilicate, said tablet composition capable of forming a colloidal solution in the stomach, whereby the carbonate or bicarbonate component (c) reacts with the acid medium in the stomach to evolve carbon dioxide gas which foams up the colloidal solution, thereby filling the lower oesophagus with a long lasting foam containing the active glycyrrhetinic acid component (a) which remains in contact with the inflammatory site in the oesophagus for a time sufficient to promote prolonged and beneficial results.
Claim 2
Dependent Claim
198 words
A pharmaceutical composition in uncoated tablet dosage unit form useful for treating oesophagitis comprising (a) 1-100 mg. of at least one member selected from the group consisting of glycyrrhetinic acid, the hemiesters thereof, and the salts of the hemiesters, in admixture with (b) 1-50% by weight of at least one member selected from the group consisting of alginic acid, the non-toxic salts of alginic acid, the carboxyalkyl-cellulose and the non-toxic salts of the carboxyalkyl-celluloses, (c) 1-30% by weight of at least one member selected from the group consisting of the non-toxic carbonates and bicarbonates and (d) 0-30% by weight of at least one antacid compound selected from the group consisting of aluminum hydroxide, aluminum phosphate, dihydroxyaluminum aminoacetate, magnesium hydroxide, and magnesium trisilicate, said tablet composition capable of forming a colloidal solution in the stomach, whereby the carbonate or bicarbonate component (c) reacts with the acid medium in the stomach to evolve carbon dioxide gas which foams up the colloidal solution, thereby filling the lower oesophagus with a long lasting foam containing the active glycyrrhetinic acid component (a) which remains in contact with the inflammatory site in the oesophagus for a time sufficient to promote prolonged and beneficial results.
Claim 3
Dependent Claim
21 words
A pharmaceutical composition according to claim 1, wherein said uncoated tablet dosage unit has a weight of 0.20 - 5.0 g.
Claim 4
Dependent Claim
21 words
A pharmaceutical composition according to claim 1, wherein said uncoated tablet dosage unit has a weight of 0.7 - 2.6 g.
Claim 5
Dependent Claim
24 words
A pharmaceutical composition according to claim 1, wherein the glycyrrhetinic acid component (a) is present in an amount of from 10 - 50 mg.
Claim 6
Dependent Claim
22 words
A pharmaceutical composition according to claim 1, wherein component (b) is present in an amount of from 10 - 40% by weight.
Claim 7
Dependent Claim
22 words
A pharmaceutical composition according to claim 1, wherein component (c) is present in an amount of from 3 - 10% by weight.
Claim 8
Dependent Claim
22 words
A pharmaceutical composition according to claim 1, wherein component (d) is present in an amount of from 5 - 15% by weight.
Claim 9
Dependent Claim
21 words
A pharmaceutical composition according to claim 1, wherein the glycyrrhetinic acid component (a) is the disodium salt of glycyrrhetinic acid hemisuccinate.
Claim 10
Dependent Claim
31 words
A pharmaceutical composition according to claim 1, which additionally comprises at least one member selected from the group consisting of pharmaceutical diluents and carriers, flavouring agents, sweetening agents and colouring materials.
Claim 11
Dependent Claim
155 words
A pharmaceutical composition in uncoated tablet dosage unit form, useful for treating oesophagitis comprising (a) 10-50 mg. of the disodium salt of glycyrrhetinic acid hemisuccinate in admixture with (b) 10- 40% by weight of alginic acid of carboxymethycellulose (c) 3-10% by weight sodium bicarbonate and (d) 5-15% by weight of at least one antacid compound selected from the group consisting of aluminum hydroxide, aluminum phosphate, dihydroxyaluminum aminoacetate, magnesium hydroxide, and magnesium trisilicate, said tablet composition capable of forming a colloidal solution in the stomach, whereby the carbonate or bicarbonate component (c) reacts with the acid medium in the stomach to evolve carbon dioxide gas which foams up the colloidal solution, thereby filling the lower oesophagus with a long lasting foam containing the active glycyrrhetinic acid component (a) therein, thus ensuring that the active component (a) remains in contact with the inflammatory site in the oesophagus for a time sufficient to promote prolonged and beneficial results.
Claim 12
Dependent Claim
155 words
A pharmaceutical composition in uncoated tablet dosage unit form, useful for treating oesophagitis comprising (a) 10-50 mg. of the disodium salt of glycyrrhetinic acid hemisuccinate in admixture with (b) 10- 40% by weight of alginic acid of carboxymethycellulose (c) 3-10% by weight sodium bicarbonate and (d) 5-15% by weight of at least one antacid compound selected from the group consisting of aluminum hydroxide, aluminum phosphate, dihydroxyaluminum aminoacetate, magnesium hydroxide, and magnesium trisilicate, said tablet composition capable of forming a colloidal solution in the stomach, whereby the carbonate or bicarbonate component (c) reacts with the acid medium in the stomach to evolve carbon dioxide gas which foams up the colloidal solution, thereby filling the lower oesophagus with a long lasting foam containing the active glycyrrhetinic acid component (a) therein, thus ensuring that the active component (a) remains in contact with the inflammatory site in the oesophagus for a time sufficient to promote prolonged and beneficial results.
Claim 13
Dependent Claim
101 words
A method of treating oesophagitis, which comprises administering to a human suffering from oesophagitis, a pharmaceutical composition according to claim 1; which composition forms a colloidal solution in the stomach, whereby the carbonate or bicarbonate component (c) reacts with the acid medium in the stomach to evolve carbon dioxide gas which foams up the colloidal solution, thereby filling the lower oesophagus with a long lasting foam containing the active glycyrrhetinic acid component (a) therein, thus ensuring that the active component (a) remains in contact with the inflammatory site in the oesophagus for a time sufficient to promote prolonged and beneficial results.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-03-16 | 1979-09-15 | 1980-03-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-03-16 | 1983-09-15 | 1984-03-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-03-16 | 1987-09-15 | 1988-03-16 | $7700.00 | Window Closed / Lapsed |